Remove 2025 Remove HIV Treatment and Prevention Agents Remove Labelling
article thumbnail

Year In Review: Top Infectious Diseases Articles From 2024

ID Stewardship

I wonder if this will cause us to be more fragmented as a group in 2025 and if Bluesky will really have sticking power. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | NEJM PURPOSE 1 RCT : No participants receiving twice-yearly lenacapavir acquired HIV infection. Mastodon sure did not.